CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 120 enrolled
Drug / intervention
F# 13418-148 Eye Drops +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03198000
NCT03198000Phase 3Completed
CompareCT.gov

A Single-Center, Randomized, Controlled Study to Evaluate the Efficacy of Two Investigational OTC Eye Drops in Healthy Adults With Red Eye

Johnson & Johnson Consumer Inc. (J&JCI)·interventional·Posted Jun 23, 2017·Updated May 24, 2023

In Brief

A Phase 3 clinical trial evaluating F# 13418-148 Eye Drops, F#13418-158 Eye Drops, and 1 other intervention for Ophthalmic Solutions. Completed, enrolled 120 participants across 1 site.

Detailed Summary

This is a single center, double-blinded study designed to demonstrate the therapeutic equivalence of over-the-counter eye drops in healthy adults with red eyes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOphthalmic Solutions
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJun 23, 2017
Enrollment StartJun 28, 2017
Primary CompletionJul 21, 2017
TodayJul 2, 2026
Enrollment to primary: 23 daysPosted 9.0 years ago

Interventions

F# 13418-148 Eye Dropsdrug

ocular clear liquid. Tetrahydrozoline 0.05%; Glycerin 0.40% 1-2 drops will be instilled as instructed over one day

F#13418-158 Eye Dropsdrug

ocular clear liquid Tetrahydrozoline 0.05%; Glycerin 0.20%, Hypromellose 0.2%, Polyethylene glycol 400 1.0% 1-2 drops will be instilled as instructed over one day

F# PF-004390 Eye Dropsdrug

Ocular clear liquid Tetrahydrozoline 0.05%; 1-2 drops will be instilled as instructed over one day